You just read:

TECOS, Merck's Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes

News provided by

Merck Canada Inc.

Jun 10, 2015, 07:00 ET